Status: Available
An Intermediate Expanded Use Trial of DFMO
To provide DFMO in an expanded use setting to subjects with relapsed rare tumors with increased LIN28 expression or MYCN amplification or up regulation of ornithine decarboxylase.
Trial details
Age: 0-30Biological sex: AllType: Expanded AccessSponsor: Giselle ShollerUpdated: Feb 20, 2026Locations: 1
Eligibility criteria
Age: 0-30 years at the time of initial diagnosis. [+9]
BSA (m2) of <0.25 [+1]